Vesicare launched in Algeria
Algiers, Algeria 10 September 2015. Astellas Middle East, North and Sub-Saharan Africa (MENA/SSA) announced that a new treatment, Solifenacin succinate, has been made available in Algeria for relieving symptoms of overactive bladder (OAB) in adults.1 This includes patients suffering from a strong, sudden urge to urinate without prior warning and having to urinate frequently.1 This treatment has been developed by Astellas, and it has been already marketed in 78 countries worldwide.
OAB affects more than 400 million people worldwide.2 The symptoms of OAB can have a profound effect on an individual’s quality of life, as well as impacting social, family, physical and professional settings.3
Solifenacin succinate is an antimuscarinic drug that is believed to help prevent voluntary and involuntary bladder contractions by blocking certain receptors on the bladder muscles, thereby help the bladder to expand to its full size before signalling to the brain that it is necessary to urinate.1
Pr. Abderrezak Dahdouh, Professor of Urology at the Clinique el Daksi in Constantine, commented: “Treating patients with this medication was studied in several controlled clinical trials in adult men and women with overactive bladder symptoms. After 12 weeks of treatment, approximately 50% of patients suffering from incontinence before treatment were free of incontinence episodes. Treatment of the symptoms of overactive bladder also resulted in improving patients’ quality of life.”
Speaking to media, Dr. Karim Hachi, Doctor of Urology in Algiers commented: “Solifenacin succinate’s availability in the Algerian market will give physicians the option of prescribing a globally well-known treatment to OAB patients. Solifenacin showed to be a specific antagonist for Muscarinic receptors by displaying low or no affinity for other receptors, hence associated with less common adverse events. Relief of urinary symptoms with Solifenacin is usually within one week of starting treatment and is most effective after 3 months of treatment.”
Solifenacin succinate is available as a once-daily sustained release formulation and in two dosage strengths (5mg and 10mg tablet) that allows easy dose titration for patients requiring additional relief. Long-term safety, efficacy, tolerability and persistence with treatment have been established in an open label 40 week continuation study.4
“We are very pleased to be launching Solifenacin succinate in Algeria. Astellas has well established its leading position in urology globally with wider activity in Lower Urinary Tract Symptoms (LUTS) associated with benign Prostatic Hyperplasia (BPH) in addition to OAB. We are as committed to improving the quality of life of our patients in Algeria as we are in all our markets. The introduction of VESICARE will offer existing patients and those newly diagnosed with OAB a real alternative to current treatments, commented Dr. Djouamai, Khaled, Area Manager Maghreb, Astellas MENA/SSA.
– ENDS –
- Vesicare HCP Website, Mechanism of Action [Accessed on 10-AUG-2015]; https://www.medicines.org.uk/emc/medicine/19113
- Irwin D.E., et al. Worldwide prevalence estimates of lower urinary tract symptoms, overactive bladder, urinary incontinence and bladder outlet obstruction. BJU Int 2011; 108(7):1132-8
- Brown JS et al. Comorbidities associated with overactive bladder. Am J Manag Care 2000; 6(11 Suppl):S574-579
- Haab F et al. ; Long-term open-label solifenacin treatment associated with persistence with therapy in patients with overactive bladder syndrome; Eur Urol. 2005 Mar;47(3):376-84. Epub 2005 Jan 5.
- Abrams P. et al. Reviewing the ICS 2002 Terminology Report: The Ongoing Debate. Neurourol Urodyn 2006; 25: 293-294